News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 37–59
- Matches
- 59
- Sources here
- 14
- Companies here
- 1
Active search
59 matching headlines
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Biohaven Pharmaceutical Holding Company Ltd (BHVN) Earnings, Actual EPS, EPS Estimates & Results
This article provides detailed earnings information for Biohaven Pharmaceutical Holding Company Ltd (BHVN), including actual EPS, EPS estimates, and results. It highlights upcoming Q2 '26 earnings with an estimated EPS of -$0.75 and an estimated revenue of $0M. The company's historical quarterly performance shows …
Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload
Biohaven Ltd. will present new Phase 1 clinical data on its FGFR3-directed antibody-drug conjugate (ADC) BHV-1530 at the ESMO Congress 2026. The data shows early tumor reductions in various advanced solid tumors with a differentiated safety profile, and Biohaven has also partnered with Regeneron …
How Biohaven’s (BHVN) R&D Leadership Shuffle Will Impact Investors
Biohaven Ltd. recently reshuffled its R&D leadership, with Chief Scientific Officer Bruce Car transitioning to a part-time Chief Innovation Officer role and David Pirman promoted to head of discovery. This reorganization aims to separate external innovation from internal discovery, which could clarify accountability but …
Biohaven files Form 3 for Chief Legal Officer Warren Karl Volles
Biohaven's Chief Legal Officer, Warren Karl Volles, has filed a Form 3, disclosing ownership of 248,212 common shares and stock options for 731,000 shares. This disclosure was made public via the U.S. SEC's EDGAR system on July 17, 2026. The information was initially created …
Biohaven Ltd. (NYSE: BHVN) legal chief discloses holdings
Biohaven Ltd.'s Chief Legal Officer, Warren Karl Volles, has filed an initial statement of beneficial ownership, disclosing holdings including 248,212 Common Shares acquired directly and through an employee plan, 14,000 restricted share units, and various stock options totaling over 700,000 underlying common shares. These …
Lobbying Update: $120,000 of BIOHAVEN LTD. lobbying was just disclosed
BIOHAVEN LTD. (BHVN) recently disclosed $120,000 in lobbying expenditures for Q2 2026, primarily focused on advocacy for patients with rare diseases. The article also details recent hedge fund activity, showing significant adds and removals of BHVN shares, and lists price targets from six analysts …
Price to book forward of Biohaven Ltd. – NYSE:BHVN
The article provides a brief financial snippet for Biohaven Ltd. (NYSE: BHVN), specifically focusing on its "Price to book forward" metric. It appears to be a data point derived from a financial platform, showing the value and change for this specific period. The content …
Discipline and Rules-Based Execution in BHVN Response
This article provides an analysis of Biohaven Ltd. (BHVN) leveraging AI models to generate trading strategies across different risk profiles. It highlights near-term weak sentiment, identifies potential long-term weakness, and offers specific entry, target, and stop-loss levels for position trading, momentum breakout, and risk …